Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Braintree, MA.

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel

Microbot Medical Shares Status Following Recent Geopolitical Events

ExScientia Ltd

Guardforce AI Co Ltd

Excitement over the prospects for artificial intelligence (AI) continues to be a significant driver for many stocks, including several of the so-called Magnificent Seven.

3 AI Stocks Wall Street Expects to Return Up to 595% in 2024

Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

All of the cash payable to the plaintiffs in the settlement will be covered by Microbot's insurance carrier and will not impact company's cash position All of the cash payable to the plaintiffs in the settlement will be covered by Microbot's insurance carrier and will not impact company's cash position

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

Microbot Medical (MBOT) Announces Positive GLP Study Results

BRAINTREE, Mass., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 1,685,682 shares of common stock, having exercise prices ranging from $2.075 to $3.19 per share, issued by Microbot in October 2022 and June 2023, at a reduced exercise price of $1.62 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to an effective resale registration statement on Form S-1 (File No. 333-273207). The closing of the offering is expected to occur on or about January 3, 2024, subject to satisfaction of customary closing conditions.

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

New York, December 28, 2023 – Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists.

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

The results of the study will support the Company's IDE submission to the FDA to commence its human clinical study The results of the study will support the Company's IDE submission to the FDA to commence its human clinical study

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic

Asensus Surgical

Globus Medical

Every now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy. Sure, you can gamble on just about anything these days and a non-zero probability exists for their upside.

3 Stocks at the Forefront of Medical Robotics

The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company's IDE submission to the FDA to commence its human clinical study.

Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase.

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA

Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process

BRAINTREE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done®” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular procedures using the device.

Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office

Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study

The Company's designated N otified B ody confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR

Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024

BRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York, approved Microbot's motion for summary judgment and dismissed with prejudice the previously announced Section 10(b) counterclaim brought by defendant as against Microbot in the action titled Microbot Medical Inc., Plaintiff v. Joseph Mona, Defendant.

Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study.

Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System

The engagement is an additional step in the Company's path towards marketing clearance with the FDA The engagement is an additional step in the Company's path towards marketing clearance with the FDA

Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial

The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercialization The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercialization

Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System

Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union

News for Microbot Medical Stock (MBOT)